Posted by Michael Wonder on 06 Jul 2017
Brexit must not disrupt drug R&D, say pharma chiefs
6 July 2017 - Industry lobbying began shortly after British referendum last June.
The UK’s withdrawal from the EU must not be allowed to disrupt the development of new medicines to treat cancer, diabetes and heart disease, pharma industry leaders have warned.
A letter to the FT signed by senior executives at several big pharma companies with substantial bases in the UK, says the current pan-European regulations and standards must be maintained to protect patient safety and public health.
